BioMedTracker will be offering KOL Reports and Physician Pulse Surveys through 2014 for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.

LCZ696 is a linked molecule consisting of Valsartan, an angiotensin receptor blocker, and a neutral endopeptidase inhibitor, which increases natriuretic peptides, leading to reduced blood pressure among other benefits. The PARADIGM-HF study studied patients with heart failure and reduced ejection fraction (HFrEF) in comparison with enalipril, an ACE inhibitor. The study was just closed early, as LCZ696 increased time to first occurrence of either cardiovascular death or heart failure hospitalization, though details have not been released. We surveyed 10 US Cardiologists to get a preview of how they would use LCZ696 under different assumptions about what the study found.

To purchase the Congestive Heart Failure Pulse Survey, click the link at the top of the page.

For our disclosures, please read the BioMedTracker Research Standards.